

June 27, 1967

Dr. Joseph Bird  
Sterling-Winthrop Research Institute  
Rensselaer, New York 12144

Dear Joe,

I should like to report on my recent presentation of the cyclazocine-depression data to the ECDEU investigators in Montreal. The material was presented at a symposium on anti-depressant drugs and more than 30 investigating teams were represented.

Since the only other optimistic notes were centered about a report from Paris on chlorimipramine and references to multiple ECT (Blachly et al., University of Oregon), much interest was shown our report. The best suggestion was made by Dr. Cole who indicated a willingness to use cyclazocine in the present NIMH depression study program. Eight hospitals are studying standard antidepressant drugs and cyclazocine may be introduced in the treatment failures. The study is controlled by Dr. Raskin of the Psychopharmacology Study Branch, NIMH. The units most likely to be interested are Dr. Cole/DiMascio at Boston State; and Dr. Tyce at Rochester (Minnesota) State. But Dr. Raskin indicated a willingness to call a meeting of the investigators later this summer and the investigators could be polled.

Other units which expressed an interest and could test cyclazocine are:

Drs. H. Lehmann and Ba~~W~~, Montreal.  
Dr. A. Kurland, Spring Grove State Hospital,  
Baltimore  
Dr. Donald Klein, Hillside Hospital

I would be pleased to discuss the next step at our visit next Thursday.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp

cc: Dr. Freedman